SEEL

Seelos Therapeutics, Inc. Common Stock

Delisted

SEEL was delisted on the 15th of October, 2024.

 

About: Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.

Employees: 8

Price charts implemented using Lightweight Charts™